Clinical Trial

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Study acronym: RAINBO
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The RAINBO umbrella program consists of four clinical trials investigating new adjuvant therapies in endometrial cancer patients. Eligible patients will be assigned to one of the four RAINBO trials based on the molecular profile of their cancer: * p53 abnormal endometrial cancer patients to the p53abn-RED trial * mismatch repair deficient endometrial cancer patients to the MMRd-GREEN trial * no specific molecular profile endometrial cancer patients to NSMP-ORANGE trial * POLE mutant endometrial cancer patients to the POLEmut-BLUE trial
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-02-15; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2022-07-12
Trial Details
NCT Number NCT05255653
Lead Sponsor Leiden University Medical Center
Collaborators: Institute Gustave Roussy (sponsor p53abn-RED trial), Leiden University Medical center (sponsor MMRd-GREEN trial), University College London (sponsor NSMP-ORANGE trial), Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial), Dutch Gynaecological Oncology Group, Comprehensive Cancer Centre The Netherlands, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR)
Conditions Endometrial Cancer
Enrollment 1,615 participants
Start Date 2021-11-11
Primary Completion 2030-01-01 (estimated)
Study Completion 2031-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15